Nā Hualoaʻa Hoʻohiki no ka CD7 CAR-T Therapy i ka Mālama ʻana i ka Relapsed/Refractory Peripheral T-Cell Lymphoma ma ASH 2024

Ma ka Hālāwai Makahiki 66 o ka American Society of Hematology (ASH) 2024, i mālama ʻia mai Dekemaba 7 a 10 ma San Diego, ua hōʻike ʻo Polopeka Lu Peihua o ka Halemai ʻo Lu Daopei i kahi hoʻokolohua lapaʻau Phase I o ka lāʻau lapaʻau CD7-targeted Chimeric Antigen Receptor T-cell (CAR-T) no ka mālama ʻana i ka peripheral relapsed/refractory. Lymphoma T-Cell (R/R PTCL). He holomua koʻikoʻi kēia i ka mālama ʻana i nā maʻi ʻino o nā cell T, kahi i kaupalena ʻia ai nā koho lapaʻau i loaʻa a ʻaʻole i kūpono loa.

Ua ʻike ʻia ʻo R/R PTCL no kona prognosis maikaʻi ʻole, ʻoi aku hoʻi i nā poʻe maʻi i loaʻa i nā laina lapaʻau he nui, me ka allogeneic hematopoietic stem cell transplantation (allo-HSCT). ʻOiai kēia, ua hōʻike ka lāʻau lapaʻau CD7 CAR-T, ʻo ia hoʻi ka NS7CAR-T cell therapy i hoʻomohala ʻia e ka hui a Prof. Lu, i nā hopena hoʻoikaika i ka mālama ʻana i nā poʻe maʻi me CD7-positive R/R PTCL. Ma kēia hoʻokolohua, ua kākau inoa ʻia he ʻelima mau maʻi, mai 39 a 60 mau makahiki, me nā pae holomua o R/R PTCL ma waena o ʻApelila 2021 a me Nowemapa 2023. Ua loaʻa i kēia mau maʻi ka awelika o ʻeono mau laina lapaʻau mua, me hoʻokahi hihia me ka mōʻaukala o ka hoʻoili ʻana o nā cell stem autologous.

Ua hoʻohiki maikaʻi nā hopena: i loko o ka manawa hahai waena o 234 mau lā, ua loaʻa i ka 60% o nā maʻi ke kala piha (CR), a ua loaʻa i hoʻokahi maʻi ke kala hapa (PR). ʻO ka mea nui, ua hōʻike ka lāʻau lapaʻau i kahi kiʻekiʻe o ka hoʻonui ʻana o nā cell CAR-T a me ke kūpaʻa i nā maʻi, me ka pae kiʻekiʻe waena o nā cell CAR-T e hōʻea ana i ka 93.5% ka pono. ʻO ka mea nui, ʻaʻohe hopena maikaʻi ʻole e like me ka neurotoxicity, a he akahai ka cytokine release syndrome (CRS), me hoʻokahi wale nō maʻi e ʻike nei i ka CRS papa II. Ua hiki ke hoʻokele ʻia ke ʻano palekana, me ka ʻike ʻole ʻia o nā ʻawaʻawa koʻikoʻi.

Hōʻike ka noiʻi a Polopeka Lu i ka hiki o ka lāʻau lapaʻau CD7 CAR-T ma ke ʻano he mea hoʻololi pāʻani i ka mālama ʻana i nā maʻi ʻino T-cell, ʻoi aku hoʻi i nā poʻe maʻi i loaʻa kakaikahi a ʻaʻohe koho lapaʻau i koe. Ma waho aʻe o nā hopena maikaʻi ma PTCL, ua hoʻokō mua ka hui a Polopeka Lu i ka pono koʻikoʻi i ka mālama ʻana i ka T-cell acute lymphoblastic leukemia (T-ALL) a me ka T-cell lymphoblastic lymphoma (T-LBL), me kahi kokoke i 95% ka nui o ka hoʻomaha piha ʻana i loko o kahi hui o 60 mau maʻi. Ma muli o kēia mau hopena, ke hoʻonui nei ka hui i kā lākou noiʻi ʻana i nā maʻi hematological ʻē aʻe e like me ka acute myeloid leukemia (AML), me nā ʻikepili mua e hōʻike ana i kahi 70% ka nui o ka hoʻomaha piha ʻana i nā poʻe maʻi AML CD7-positive.

ʻOiai kēia mau hopena maikaʻi, ua hoʻoikaika ʻo Polopeka Lu i ke koʻikoʻi o ka hoʻohui ʻana i ka lāʻau lapaʻau CD7 CAR-T me ka allo-HSCT e hoʻomaikaʻi i nā hopena lōʻihi. ʻO ka ʻokoʻa o nā maʻi ʻino T-cell e pono ai kahi hoʻolālā lapaʻau piha e hoʻonui i nā manawa kūpono o ke kala mau loa a me ka hiki ke ho'ōla. Ke hoʻomau nei ka hui i ka hoʻomaʻemaʻe ʻana i kā lākou ala a hoʻonui i nā hōʻailona therapeutic no ka lāʻau lapaʻau CD7 CAR-T.

ʻO ka hana paionia a Polopeka Lu, ka mea i mālama mua i nā maʻi he 300 me ka lāʻau lapaʻau CD7 CAR-T, he ʻanuʻu nui i mua i ka mālama ʻana i ka maʻi ʻino o nā cell T. I ka neʻe ʻana i mua, ua kūpaʻa ka hui i nā hoʻokolohua lapaʻau hou aʻe a me ka hoʻomaʻemaʻe ʻana i nā ʻano hana lapaʻau cell CAR-T, e hōʻoiaʻiʻo ana e pōmaikaʻi hou aku nā maʻi mai kēia ʻano hana hou.

Hōʻike kēia hoʻokolohua Māhele I hoʻohiki ma ASH 2024 i ka hiki o ka lāʻau lapaʻau CD7 CAR-T ma ke ʻano he palena hou i ka oncology hematological, e hāʻawi ana i ka manaʻolana no nā maʻi me nā kūlana i hiki ʻole ke mālama ʻia ma mua.